Quality Control & MSDS
View current batch:
|Chemical Name||HGH FRAG 176-191|
|One Letter Sequence||YLRIVQCRSVEGSCGF|
|Three Letter Sequence||H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH|
|Molecular Weight (MW)||1817.1|
|Storage||Lyophilized HGH FRAG 176-191 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FST should be stored at 4°C between 2-7 days and for future use below -18°C.|
HGH FRAG 176-191 is an anti-obesity drug .
HGH FRAG 176-191 is a synthetic peptide containing the C-terminal fragment of human growth hormone (hGH). It has been found to induce hyperglycemia and insulin resistance. Meanwhile, HGH FRAG 176-191 is a drug of anti-obesity effects since it promotes fat metabolism through selectively mimicking the activity of growth hormone on adipose tissue and increasing lipolysis. In mice model of obesity, the administration of HGH FRAG 176-191 resulted in weight loss fat mass reduction associated with increased expression level of the β3-adrenergic receptors (β3-ARs), suggesting that β3-AR played a crucial role in the chronic effectiveness of HGH FRAG 176-191 administration [1, 2 and 3].
1. Caterson I D, Finer N. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pacific, 2006, 15: 55-62.
2. Ng F M, Bornstein J, Pullin C E, et al. The minimal amino acid sequence of the insulin-potentiating fragments of human growth hormone: its mechanism of action. Diabetes, 1980, 29(10): 782-787.
3. Heffernan M, Summers R J, Thorburn A, et al. The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β 3-AR Knock-Out Mice. Endocrinology, 2001, 142(12): 5182-5189.